Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...
Medpage Today on MSN15d
FreeStyle Libre 3 Sensor Class I Recall; Second OTC CGM Cleared; Weekly Insulin WinThe FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...
The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...
Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...
Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.
Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 million diabetes patients by offering continuous glucose monitoring with ...
Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...
Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...
GlobalData on MSN15d
Abbott rolls out AVEIR DR leadless pacemaker across UKAbbott claims AVEIR DR is the world's first dual chamber leadless pacing system, which is designed to treat people with abnormal or slow heart rhythms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback